Abstract:Aims: To test whether circulating neurotoxic autoantibodies increase in adult type 2 diabetes mellitus with Parkinson’s disease (PD) or dementia. To identify the G-protein coupled receptor on neuroblastoma cells mediating neural inhibitory effects in diabetic Parkinson’s disease plasma autoantibodies. To determine the mechanism of accelerated neuroblastoma cell death and acute neurite retraction induced by diabetic Parkinson’s disease and dementia autoantibodies. Methods: Protein-A eluates from plasma of twelve older adult male diabetic patients having Parkinson’s disease (n=10) or dementia (n=2), and eight age-matched control diabetic patients were tested for ability to cause accelerated N2A neuroblastoma cell death and acute neurite retraction. Specific antagonists of G protein coupled receptors belonging to the G alpha q subfamily of heterotrimetric G-proteins, the phospholipase C/inositol triphosphate/Ca2+ pathway, or the RhoA/Rho kinase pathway were tested for ability to block diabetic Parkinson’s disease/dementia autoantibodyinduced neurite retraction or N2A accelerated cell loss. Sequential Liposorber LA-15 dextran sulfate cellulose/protein-A affinity chromatography was used to obtain highlypurified fractions of diabetic Parkinson’s disease autoantibodies . Results: Mean accelerated neuroblastoma cell loss induced by diabetic Parkinson’s disease or dementia autoantibodies significantly exceeded (P = 0.001) the level of N2A cell loss induced by an identical concentration of the diabetic autoantibodies in control patients without these two comorbid neurodegenerative disorders. Co-incubation of diabetic Parkinson’s disease and dementia autoantibodies with two-hundred nanomolar concentrations of M100907, a highly selective 5-HT2AR antagonist, completely prevented autoantibody-induced accelerated N2A cell loss and neurite retraction. A higher concentration (500 nM-10μM) of alpha-1 adrenergic, angiotensin II type 1, or endothelin A receptor antagonists did not substantially inhibit autoantibody-induced neuroblastoma cell death or prevent neurite retraction. Antagonists of the inositol triphosphate receptor (2-APB, 50μM), the intracellular calcium chelator (BAPTA-AM, 30 μM) and Y27632 (10 μM), a selective RhoA/Rho kinase inhibitor, each completely blocked acute neurite retraction induced by sixty nanomolar concentrations of diabetic Parkinson’s disease autoantibodies. Co-incubation with 2-APB (1-2 μM) for 8 hours’ prevented autoantibody-induced N2A cell loss. The highly-purified fraction obtained after Liposorber LA/protein-A affinity chromatography in hypertriglyceridemic diabetic dementia and Parkinson’s disease plasmas had apparent MWs > 30 kD, and displayed enhanced N2A toxicity requiring substantially higher concentrations of 5-HT2AR antagonists (M100907, ketanserin, spiperone) to effectively neutralize. Conclusion: These data suggest increased autoantibodies in older adult diabetes with Parkinson’s disease or dementia cause accelerated neuron loss via the 5-hydroxytryptamine 2 receptor coupled to inositol triphosphate receptor-mediated cytosolic Ca2+ release.

Analysis of the changes and influencing factors of the fat-free mass in patients with nasopharyngeal carcinoma undergoing radiotherapy

Circulating Neurotoxic 5-HT 2 A Receptor Agonist Autoantibodies in Adult Type 2 Diabetes with Parkinson ’ s Disease Page 3 of 11 Liposorber-LA-15 dextran sulfate cellulose chromatography

A preliminary investigation of body composition in prediction of malnutrition in patients with nasopharyngeal carcinoma

Relationship between nutrition impact symptoms and fat-free mass in patients with head and neck cancer during radiotherapy

Longitudinal Observations of the Prevalence of Nutritional Risk and Undernutrition in Patients with Head and Neck Cancer During Radiotherapy

The association analysis between fatigue and body composition loss in patients with nasopharyngeal carcinoma during radiotherapy: An observational longitudinal study

Nutritional intervention for the prognosis of nasopharyngeal carcinoma chemoradiotherapy patients: A meta-analysis

Longitudinal Body Composition Changes and the Importance of Fat-Free Mass Index in Locally Advanced Nasopharyngeal Carcinoma Patients Undergoing Concurrent Chemoradiotherapy

Critical weight loss during radiotherapy and its influencing factors in patients with head and neck cancer

Drug-induced platelet surface alterations. A possible mechanism for impaired aggregation.

Effect of chemoradiotherapy on nutrition status of patients with nasopharyngeal cancer

Body Composition and Dietary Intake in Patients with Head and Neck Cancer During Radiotherapy: a Longitudinal Study.

Could nutrition status predict fatigue one week before in patients with nasopharynx cancer undergoing radiotherapy?

Protein intake on body composition and quality of life in head and neck cancer patients undergoing radiotherapy

Dysphagia and Its Relationship with Weight Change in Head and Neck Cancer Patients Treated with Radiotherapy

Nutritional status assessment in rectal cancer patients undergoing neoadjuvant chemoradiotherapy

The correlation between the comprehensive nutrition index and quality of life of patients with nasopharyngeal carcinoma treated by intensity-modulated radiotherapy

Effect of Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy on Nutritional Status in Locoregionally Advanced Nasopharyngeal Carcinoma Patients: A Prospective Observational Study

Nutritional status of patients undergoing concurrent chemoradiotherapy for malignant tumor and its influencing factors

Antigenicity of fractions of a somatic antigen of Trypanosoma cruzi.

Effect of Body Size Change on Off-Center Cervical Point and Face Doses in Patients Undergoing Nasopharyngeal Carcinoma Radiotherapy